通过天眼查大数据分析，诺思格(北京)医药科技股份有限公司共对外投资了7家企业，参与招投标项目 10次，知识产权方面有商标信息7条，专利信息3条，此外企业还拥有行政许可3个。 来源：金融界 金融界消息 截至2025年7月30日收盘，诺思格（301333）报收于58.72元，下跌2.3%，换手率8.42%，成 交量4.81万手，成交金额2.84亿元。 天眼查商业履历信息显示，诺思格(北京)医药科技股份有限公司，成立于2008年，位于北京市，是一家 以从事研究和试验发展为主的企业。企业注册资本9658.1256万人民币，实缴资本9658.1256万人民币。 公司法定代表人为武杰。 资金流向方面，今日主力资金净流出1348.33万元，占比成交额4.74%。其中，超大单净流出497.71万 元、占成交额1.75%，大单净流出850.62万元、占成交额2.99%，中单净流出流入343.02万元、占成交额 1.21%，小单净流入1005.32万元、占成交额3.53%。 诺思格最新一期业绩显示，截至2025一季报，公司营业总收入1.73亿元、同比减少2.53%，归属净利润 2607.37万元，同比增长13.12%，扣非净利润 ...

Core Viewpoint - Citigroup's report indicates that WuXi AppTec (603259)(02359) experienced a 21% year-on-year revenue growth to 20.8 billion RMB in the first half of the year, with net profit increasing by 102% to 8.6 billion RMB, aligning with previous earnings guidance [1] Financial Performance - Revenue for the first half reached 20.8 billion RMB, reflecting a 21% increase compared to the same period last year [1] - Net profit surged by 102% to 8.6 billion RMB [1] - Excluding one-time gains, the growth rate was 26%, consistent with prior earnings announcements [1] Guidance and Outlook - Management has raised the full-year revenue guidance from the previous range of 41.5 billion to 43 billion RMB to a new range of 42.5 billion to 43.5 billion RMB [1] - Expected growth for ongoing business operations is now projected at 13% to 17%, up from the earlier forecast of 10% to 15% [1] - There is confidence in further improving the adjusted net profit margin [1] Valuation - Based on valuation metrics, Citigroup has set a target price of 95 HKD for WuXi AppTec, with a "Buy" rating [1] - An update will follow after the earnings conference call [1]

Core Viewpoint - Citigroup's report indicates that WuXi AppTec (02359) experienced a 21% year-on-year revenue growth to 20.8 billion RMB in the first half of the year, with net profit increasing by 102% to 8.6 billion RMB, aligning with previous earnings guidance [1] Financial Performance - Revenue for the first half reached 20.8 billion RMB, reflecting a 21% increase compared to the same period last year [1] - Net profit surged by 102% to 8.6 billion RMB, with a 26% increase when excluding one-time gains, consistent with prior earnings announcements [1] Guidance and Outlook - Management has raised the full-year revenue guidance from the previous range of 41.5 billion to 43 billion RMB to a new range of 42.5 billion to 43.5 billion RMB [1] - Expected growth in ongoing business is now projected at 13% to 17%, up from the earlier forecast of 10% to 15% [1] - There is confidence in further improving the adjusted net profit margin [1] Valuation - Based on valuation metrics, Citigroup has set a target price of 95 HKD for WuXi AppTec, maintaining a "Buy" rating, with plans for an update following the earnings conference call [1]

Core Viewpoint - The company Boji Pharmaceutical (300404) is actively engaged in providing research and development services for Alzheimer's disease medications [1] Group 1 - The company responded to investor inquiries on July 29, indicating its involvement in Alzheimer's drug development [1]

里昂发布研报称，将药明康德（02359）目标价从92.40港元上调至113.70港元；药明康德（603259.SH） 目标价从92.40元人民币上调至103.40元人民币，维持"跑赢大市"投资评级。 药明康德2025年第二季收入及经调整非国际财务报告准则净利润分别同比增长20%及48%，符合2025年 7月10日发布的盈利预告。公司将2025年持续经营业务收入增长指引，从10%至15%上调至13%至17%， 自由现金流指引从40亿元至50亿元人民币，上调到50亿元至60亿元人民币。考虑到上半年强劲表现，上 调后的收入指引并不显激进，并重申2025年经调整非国际财务报告准则净利润率将较2024年有所改善。 里昂相应上调药明康德2025至2027年全年收入及净利润预测，幅度分别为3%至4%及13%至17%，以反 映最新指引。 来源：新浪港股 ...

Investment Rating - The investment rating for WuXi AppTec is maintained as "Buy" [2][10]. Core Views - The TIDES business segment has shown remarkable performance, leading to an upward revision of the full-year revenue guidance [10]. - For the first half of 2025, the company reported a revenue of 20.799 billion RMB, a year-on-year increase of 20.64%, and a net profit attributable to shareholders of 8.561 billion RMB, a year-on-year increase of 101.92% [4]. - The company expects revenue growth for its continuing operations to return to double digits, with the growth rate revised from 10-15% to 13-17% [8]. Financial Performance - In H1 2025, the gross margin improved significantly to 44.45%, an increase of 5.08 percentage points year-on-year, while the net profit margin rose to 41.64%, up 16.81 percentage points year-on-year [5]. - The revenue from the chemical business reached 16.3 billion RMB, a growth of 33.5%, while the TIDES business revenue surged to 5.03 billion RMB, a staggering increase of 141.6% [6]. - The company’s total orders on hand reached 56.69 billion RMB, reflecting a year-on-year growth of 37.2% [8]. Revenue and Profit Forecast - The revenue forecast for 2025-2027 has been adjusted to 43.299 billion RMB, 49.656 billion RMB, and 56.472 billion RMB respectively, with net profit forecasts revised to 14.406 billion RMB, 13.249 billion RMB, and 15.249 billion RMB [10][12]. - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 5.02 RMB, 4.61 RMB, and 5.31 RMB respectively [10].

Core Viewpoint - Citigroup's research report indicates that WuXi AppTec (2359.HK) experienced a 21% year-on-year revenue growth to 20.8 billion RMB in the first half of the year, with net profit increasing by 102% to 8.6 billion RMB, aligning with previous earnings guidance [1] Financial Performance - Revenue for the first half of the year reached 20.8 billion RMB, marking a 21% increase compared to the previous year [1] - Net profit surged by 102% to 8.6 billion RMB, and when excluding one-time gains, the growth rate was 26% [1] Guidance and Projections - Management has raised the full-year revenue guidance from the previous range of 41.5 billion to 43 billion RMB to a new range of 42.5 billion to 43.5 billion RMB [1] - The expected growth for ongoing operations is now projected at 13% to 17%, up from the earlier forecast of 10% to 15% [1] - There is confidence in further improving the adjusted net profit margin [1] Analyst Ratings - Citigroup has set a target price of 95 HKD for WuXi AppTec, rating it as a "Buy" and plans to update after the earnings conference call [1] - Morgan Stanley has rated WuXi AppTec with a target price of 92 RMB and an "Overweight" rating, citing better-than-expected performance in the first half [1] - Bank of America has raised its target price for WuXi AppTec to 115.7 HKD, highlighting strong growth in new orders during the first half [1]

Core Viewpoint - The recent incident of two employees fighting in the office has raised concerns about the company culture at Kanglong Chemical (康龙化成) and its impact on the company's reputation and operations [1][3][4]. Company Overview - Kanglong Chemical, established in 2004, is a leading global integrated pharmaceutical research and development service platform, listed on A-share and H-share markets in 2019 [2][4]. - The company experienced a significant stock price increase, reaching a peak market value of nearly 200 billion yuan in 2021, but has since seen its market value shrink to approximately 46.8 billion yuan, a loss of over 140 billion yuan [2][7]. Financial Performance - The company's profit growth has slowed down, with a projected net profit of approximately 6.79 billion to 7.13 billion yuan for the first half of 2025, representing a year-on-year increase of 36% to 39%. However, the adjusted net profit under non-IFRS is expected to grow only by 6% to 11% [2][7]. - Kanglong Chemical's revenue growth has also decelerated, with expected revenues of 63.33 billion to 65.01 billion yuan for the first half of 2025, reflecting a year-on-year growth of 13% to 16% [7]. Shareholder Activity - There has been significant shareholder reduction in holdings, with total cashing out exceeding 20 billion yuan since 2022. The actual controller and related parties have cashed out around 3 billion yuan [2][8][9]. - Notably, major shareholders have reduced their stakes significantly, with one entity alone cashing out approximately 5.4 billion yuan [8]. Company Culture and Employee Relations - The company promotes a culture of "employees first, customers second," focusing on employee training and development [5]. - The recent incident of fighting among employees has sparked public criticism regarding the company's internal culture and management practices, with many questioning the adequacy of resources and support for employees [3][4][6].

Group 1 - The Hong Kong Monetary Authority (HKMA) Chief Executive, Eddie Yue, indicated a potential increase in Hong Kong dollar interbank rates due to reduced liquidity and recent triggers of the "weak side convertibility guarantee" [12] - As of July 11, the one-month interbank rate rose to 1.08%, while the overnight rate adjusted from near zero to 0.09% [12] - The HKMA emphasized the importance of monitoring financial market changes and maintaining monetary stability through the linked exchange rate system [12] Group 2 - The Hong Kong stock market showed mixed performance on July 11, with the Hang Seng Index rising by 0.46% to 24,139.57 points and the Hang Seng Tech Index increasing by 0.61% to 5,248.48 points [2] - Major blue-chip stocks like WuXi AppTec surged by 10.46%, while some consumer stocks like Lao Pu Gold and Pop Mart experienced declines of 11.42% and 4.14%, respectively [5][8] - The brokerage sector saw significant gains, with Zhongzhou Securities soaring by 47.47% and other firms like Guolian Minsheng and Hengtou Securities also posting substantial increases [2][4]

Group 1 - Nomura raised the target price for WuXi AppTec (603259) from HKD 84.59 to HKD 102.77 [1]